Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
J Thromb Thrombolysis
; 52(2): 542-552, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1222780
ABSTRACT
Coronavirus 2019 disease (COVID-19) is associated with coagulation dysfunction that predisposes patients to an increased risk for both arterial (ATE) and venous thromboembolism (VTE) and consequent poor prognosis; in particular, the incidence of ATE and VTE in critically ill COVID-19 patients can reach 5% and 31%, respectively. The mechanism of thrombosis in COVID-19 patients is complex and still not completely clear. Recent literature suggests a link between the presence of antiphospholipid antibodies (aPLs) and thromboembolism in COVID-19 patients. However, it remains uncertain whether aPLs are an epiphenomenon or are involved in the pathogenesis of the disease.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Tromboembolia
/
Anticuerpos Antifosfolípidos
/
SARS-CoV-2
/
COVID-19
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Animales
/
Humanos
Idioma:
Inglés
Revista:
J Thromb Thrombolysis
Asunto de la revista:
Angiología
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
S11239-021-02470-y
Similares
MEDLINE
...
LILACS
LIS